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The low-calcium concentration
of dialysate induced markedly an
increase of serum parathyroid
hormone in a continuous
ambulatory peritoneal dialysis
patient
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To the editor: Haris reported that peritoneal dialysis patients
with low turnover bone disease treated with the low-calcium
solution showed an increase of serum parathyroid hormone
(PTH) levels and improvement of bone turnover.1 However,
we experienced a 40-year-old patient on peritoneal dialysis
for chronic nephritis who showed marked change in the
volume of a parathyroid adenoma and the serum PTH level
according to changes of the calcium concentration in the
peritoneal dialysis solution. The patient was on dialysis with
2 l of peritoneal dialysis solution in four bags. After the
calcium concentration of the dialysate was reduced from 1.5
to 1.25 mM, the patient’s intact PTH (iPTH) level increased,
even though administration of activated vitamin D had
become possible. After the calcium concentration of the
dialysate was returned to 1.5 mM, the iPTH level decreased
(Figure 1). Ultrasonography of the neck revealed the
development of a parathyroid adenoma when the patient
had a high iPTH level. This adenoma disappeared after the
iPTH level decreased. Kidney/Disease Outcomes Quality
Initiative (K/DOQI) guidelines recommended the calcium
concentration of dialysate at 1.25 mM.2 However, it has
become a clinical concern that use of new drugs, such as
sevelamer hydrochloride may increase PTH levels. We
previously reported that PTH level increased significantly
after the calcium concentration of the dialysate was decreased
from 1.5 to 1.25 mM.3 Therefore, the calcium concentration
of dialysate should be determined on an individual basis
rather than uniformly.
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Yokoyama et al.1 presented a case of a 40-year-old patient
on continuous ambulatory peritoneal dialysis, whose
dialysate calcium (Ca) concentration was reduced from
1.5 to 1.25 mM. During the approximately 3 years of low Ca
treatment, the level of parathyroid hormone (PTH)
increased markedly and a parathyroid adenoma appeared.
Both the elevated level of PTH and the parathyroid
adenoma reversed after increasing the dialysate Ca
concentration back to 1.5 mM.
PTH secretion strongly depends – beside the serum
phosphate and the calcitriol concentration – on the serum-
ionized Ca level. The serum Ca concentration in a
continuous ambulatory peritoneal dialysis patient, is
determined by the ion’s absorption from the gut, from
dietary Ca intake and consumed Ca-containing phophate
binders, the net flux from bone and the net Ca loss-or-gain
from the dialysate. The latter can be positive or negative,
depending on the dialysate Ca concentration, its difference
from the patient’s ionized Ca level and the amount of
ultrafiltration.2 Hypocalcemic episodes can stimulate PTH
secretion, and even provoke adenoma formation in the
parathyroid gland. According to the findings of Duncan
et al.3 and Buijsen et al.4 the higher the baseline PTH, the
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Figure 1 | Clinical course of the patients. After the calcium
concentration of the dialysate was reduced from 1.5 to 1.25 mM, the
patient’s iPTH level increased from 180 to 990 pg/ml, even though
administration of activated vitamin D had become possible. After the
calcium concentration of the dialysate was returned to 1.5 mM, the
iPTH level decreased to 31 pg/ml.
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more significant its elevation when dialysate Ca is
decreased.
In patients with adynamic bone disease, lowering of
dialysate Ca can beneficially stimulate abnormally low
PTH secretion and hence increase bone formation rate, as
we have shown in our study.5 Nevertheless, as we have
emphasized, lowering the dialysate Ca concentration on a
long-term basis can lead to overstimulation of parathyroid
secretion. Therefore regular follow-up of the PTH level is
mandatory, and the dialysate Ca concentration needs to be
individualized according to the actual level of serum Ca
and PTH concentrations.
In Yokoyama et al. case presentation, illustrated by a
graph, the changes in the PTH levels during the use of 1.5
and 1.25 mM dialysate Ca during the 66 months of
observation is nicely shown. However the simultaneous
serum Ca level is not presented. One wonders how much of
the fluctuation in PTH levels is associated with simulta-
neously measured levels of hypo- or hypercalcemia. As well
we would be concerned with extended periods of
suppressed PTH levels, in additon to the elevated levels
which the authors have remarked on. We agree with their
suggestions in monitoring serum PTH and Ca levels
routinely so that dialysate Ca may be individualized,
according to the actual needs of the patient, especially in
cases where doses of Ca-containing phosphate binders or
vitamin D sterols are reduced.
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